As with talazoparib+avelumab, the DOMEC results highlight the difficulty of generating meaningful benefit in unselected or pMMR endometrial cancer, particularly when PD-1 monotherapy already achieves high response rates in MSI-H/dMMR disease. This evidence concerns the gene PDCD1 and endometrial cancer.